debt_leverage_profile
-0.15x Total Debt / Equity (Negative equity)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; minimal long-term debt, but rising rates increase cost of equity capital raises critical for cash-burn-stage biotech
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Single-source API manufacturer (sterile injectable drug supply) and specialized ophthalmic device components sourced from limited suppliers
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue currently; negligible sovereign currency devaluation exposure as company is primarily US-clinical-stage
Inferred
Agent_Inference
geographic_footprint
Nearly 100% US-based revenue and operations; no material foreign currency exposure in top markets
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Yes; sole-source contract manufacturer for suprachoroidal injection formulations represents non-substitutable critical input with high switching cost
Inferred
Agent_Inference
business_model_type_primary
Minimal cloud dependency; clinical-stage biotech operations could migrate platforms within 60-90 days with moderate disruption to data systems
Inferred
Agent_Inference
business_model_type_secondary
Secondary revenue from licensing/royalties (XIPERE commercialization deal with Bausch) is not cloud-dependent
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; limited SaaS integrations; primary data systems are clinical trial and regulatory databases with moderate portability
Inferred
Agent_Inference
howey_test_risk_index
Low Howey Test risk; revenue model is pharmaceutical licensing and royalties, clearly not a securities offering
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate HIPAA exposure from clinical trial patient data; limited GDPR risk given minimal EU operations; CCPA exposure low
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche suprachoroidal drug delivery platform with small market share and no dominant market position
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~80% recurring royalty/milestone revenue from Bausch licensing; ~20% transactional grant or service revenue
Inferred
Agent_Inference
monetization_vector
Royalty and milestone payments from pharmaceutical licensing partners (Bausch + Lomb XIPERE deal primary vector)
Inferred
Agent_Inference
pricing_architecture
Pricing set by licensee Bausch; Clearside receives royalty percentage, limiting direct pricing power but providing stable recurring income
Inferred
Agent_Inference
pricing_power_rating
Low direct pricing power; dependent on licensee's pricing decisions for XIPERE; royalty rate fixed contractually
Inferred
Agent_Inference
target_gross_margin_bracket
85-95% gross margin on royalty/licensing revenue; minimal COGS on royalty streams
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider problem; platform access gated by licensing agreements with contractual minimums
Inferred
Agent_Inference
headcount_cost_structure
Sublinear; revenue growth via royalties requires minimal incremental headcount; ~30-person company with scalable licensing model
Inferred
Agent_Inference
marginal_cost_of_growth
Near-zero marginal cost for incremental royalty revenue; pipeline advancement requires fixed R&D burn, not proportional headcount scaling
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, royalty economics improve dramatically; CAC effectively zero for licensing revenue, constrained by pipeline asset breadth
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; drug delivery platform value is clinical and IP-based, not user-network driven
Inferred
Agent_Inference
asset_efficiency_ratio
Low AI displacement risk; core value is proprietary suprachoroidal delivery IP and FDA-approved platform, not automatable
Inferred
Agent_Inference
recession_resistance_tier
Moderate-high recession resistance; ophthalmic disease treatment (uveitis, macular edema) is medically necessary, not discretionary
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical and biotech licensing partners (Bausch + Lomb as primary); high concentration risk with single dominant partner
Inferred
Agent_Inference
customer_segment_secondary
Government/academic research grant bodies as secondary revenue source; low concentration risk in this segment
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
58.7% CapEx / Revenue (High-CapEx Infrastructure)
High
SEC-XBRL
sec_cik
0001539029
High
SEC-EDGAR
ticker
CLSDQ
High
SEC-EDGAR